Total Payments
$320,093
2024 Payments
$57.50
Companies
24
Transactions
380
Medicare Patients
282
Medicare Billing
$46,414
Payment Breakdown by Category
Other$236,583 (73.9%)
Travel$47,785 (14.9%)
Consulting$28,027 (8.8%)
Food & Beverage$7,624 (2.4%)
Education$73.68 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $236,018 | 85 | 73.7% |
| Travel and Lodging | $47,785 | 138 | 14.9% |
| Consulting Fee | $28,027 | 15 | 8.8% |
| Food and Beverage | $7,624 | 134 | 2.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $565.00 | 1 | 0.2% |
| Education | $73.68 | 7 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $193,076 | 197 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $91,320 | 91 | $0 (2023) |
| Jazz Pharmaceuticals Inc. | $10,346 | 19 | $0 (2020) |
| Millennium Pharmaceuticals, Inc. | $8,073 | 6 | $0 (2017) |
| AbbVie, Inc. | $5,402 | 13 | $0 (2018) |
| PFIZER INC. | $5,344 | 13 | $0 (2019) |
| Janssen Biotech, Inc. | $3,484 | 8 | $0 (2019) |
| Adaptive Biotechnologies Corporation | $1,511 | 2 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $500.00 | 1 | $0 (2017) |
| Janssen Scientific Affairs, LLC | $305.20 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $57.50 | 2 | Alexion Pharmaceuticals, Inc. ($35.34) |
| 2023 | $55,034 | 51 | E.R. Squibb & Sons, L.L.C. ($54,875) |
| 2022 | $36,731 | 46 | E.R. Squibb & Sons, L.L.C. ($35,110) |
| 2021 | $28,149 | 34 | Celgene Corporation ($26,838) |
| 2020 | $42,311 | 38 | Celgene Corporation ($42,107) |
| 2019 | $73,886 | 88 | Celgene Corporation ($55,961) |
| 2018 | $47,900 | 65 | Celgene Corporation ($41,026) |
| 2017 | $36,025 | 56 | Celgene Corporation ($27,105) |
All Payment Transactions
380 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/06/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $35.34 | General |
| Category: Rare Disease | ||||||
| 01/09/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: Oncology | ||||||
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,566.00 | General |
| Category: Hematology | ||||||
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Travel and Lodging | Cash or cash equivalent | $31.44 | General |
| Category: Hematology | ||||||
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Travel and Lodging | Cash or cash equivalent | $20.00 | General |
| Category: Hematology | ||||||
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $18.18 | General |
| Category: Hematology | ||||||
| 10/19/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Travel and Lodging | Cash or cash equivalent | $731.73 | General |
| Category: Hematology | ||||||
| 10/19/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Travel and Lodging | Cash or cash equivalent | $473.24 | General |
| Category: Hematology | ||||||
| 10/19/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Travel and Lodging | Cash or cash equivalent | $215.46 | General |
| Category: Hematology | ||||||
| 10/19/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $124.46 | General |
| Category: Hematology | ||||||
| 08/15/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,995.00 | General |
| Category: Hematology | ||||||
| 08/15/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,141.50 | General |
| Category: Hematology | ||||||
| 08/15/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Travel and Lodging | Cash or cash equivalent | $273.80 | General |
| Category: Hematology | ||||||
| 08/15/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $21.86 | General |
| Category: Hematology | ||||||
| 07/19/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Travel and Lodging | Cash or cash equivalent | $185.24 | General |
| Category: Hematology | ||||||
| 07/19/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $98.90 | General |
| Category: Hematology | ||||||
| 07/18/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Travel and Lodging | Cash or cash equivalent | $841.80 | General |
| Category: Hematology | ||||||
| 07/18/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Travel and Lodging | Cash or cash equivalent | $158.85 | General |
| Category: Hematology | ||||||
| 06/15/2023 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,664.00 | General |
| 06/06/2023 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,664.00 | General |
| 05/11/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $1,045.77 | General |
| 05/10/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,849.00 | General |
| Category: Hematology | ||||||
| 05/10/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,849.00 | General |
| Category: Hematology | ||||||
| 05/10/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Travel and Lodging | Cash or cash equivalent | $188.00 | General |
| Category: Hematology | ||||||
| 05/10/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 3 | 49 | 105 | $24,032 | $8,759 |
| 2021 | 5 | 85 | 187 | $38,669 | $15,565 |
| 2020 | 4 | 148 | 331 | $63,598 | $22,091 |
Total Patients
282
Total Services
623
Medicare Billing
$46,414
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 64 | $11,712 | $4,944 | 42.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 18 | 23 | $7,820 | $2,543 | 32.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 17 | 18 | $4,500 | $1,271 | 28.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 113 | $20,679 | $8,929 | 43.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 15 | $5,340 | $2,296 | 43.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 16 | 24 | $6,048 | $2,237 | 37.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 13 | 13 | $2,444 | $1,055 | 43.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 20 | 22 | $4,158 | $1,048 | 25.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 71 | 135 | $25,515 | $7,789 | 30.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 23 | 86 | $15,738 | $6,474 | 41.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 36 | 67 | $16,884 | $5,628 | 33.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 18 | 43 | $5,461 | $2,199 | 40.3% |
About Dr. Michael Dugan, M.D
Dr. Michael Dugan, M.D is a Hematology & Oncology healthcare provider based in Indianapolis, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437263399.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Dugan, M.D has received a total of $320,093 in payments from pharmaceutical and medical device companies, with $57.50 received in 2024. These payments were reported across 380 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($236,018).
As a Medicare-enrolled provider, Dugan has provided services to 282 Medicare beneficiaries, totaling 623 services with total Medicare billing of $46,414. Data is available for 3 years (2020–2022), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Indianapolis, IN
- Active Since 08/18/2006
- Last Updated 10/26/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1437263399
Products in Payments
- Revlimid (Drug) $131,553
- Pomalyst (Drug) $80,706
- INREBIC (Drug) $14,762
- ONUREG (Drug) $13,992
- ABECMA (Biological) $11,708
- NINLARO (Drug) $8,073
- Inrebic (Drug) $7,775
- Venclexta (Drug) $5,402
- MYLOTARG (Biological) $4,403
- VYXEOS (Drug) $3,654
- DARZALEX (Biological) $3,651
- clonoSEQ (Device) $1,511
- BENDEKA (Drug) $500.00
- SOLIRIS (Drug) $147.79
- Kyprolis (Drug) $125.00
- DARZALEX (Drug) $109.80
- XOSPATA (Drug) $104.95
- Imbruvica (Drug) $52.72
- ADCETRIS (Biological) $46.33
- Horizant (Drug) $41.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Indianapolis
Mr. Ruemu Birhiray, Md, MD
Hematology & Oncology — Payments: $3.3M
Hematology & Oncology $3.3M
Dr. Richard Gaynor, M.d, M.D
Hematology & Oncology — Payments: $3.2M
Hematology & Oncology $3.2M
Anand Tandra, M.d, M.D
Hematology & Oncology — Payments: $257,904
Hematology & Oncology $257,904
Dr. John Edwards, Md, MD
Hematology & Oncology — Payments: $193,104
Hematology & Oncology $193,104
Dr. Brandon Hardesty, M.d, M.D
Hematology & Oncology — Payments: $98,240
Hematology & Oncology $98,240
Kathy Miller, Md, MD
Hematology & Oncology — Payments: $79,815
Hematology & Oncology $79,815